ZA202212128B - Combination of alcaftadine and a corticosteroid - Google Patents
Combination of alcaftadine and a corticosteroidInfo
- Publication number
- ZA202212128B ZA202212128B ZA2022/12128A ZA202212128A ZA202212128B ZA 202212128 B ZA202212128 B ZA 202212128B ZA 2022/12128 A ZA2022/12128 A ZA 2022/12128A ZA 202212128 A ZA202212128 A ZA 202212128A ZA 202212128 B ZA202212128 B ZA 202212128B
- Authority
- ZA
- South Africa
- Prior art keywords
- alcaftadine
- corticosteroid
- pharmaceutically acceptable
- acceptable salt
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921053286 | 2020-06-15 | ||
| PCT/IB2021/055222 WO2021255622A1 (en) | 2020-06-15 | 2021-06-14 | Combination of alcaftadine and a corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202212128B true ZA202212128B (en) | 2024-04-24 |
Family
ID=76523259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/12128A ZA202212128B (en) | 2020-06-15 | 2022-11-07 | Combination of alcaftadine and a corticosteroid |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230218630A1 (enExample) |
| EP (1) | EP4164614A1 (enExample) |
| JP (1) | JP7791119B2 (enExample) |
| KR (1) | KR20230024928A (enExample) |
| CN (1) | CN115701988A (enExample) |
| AU (1) | AU2021291684A1 (enExample) |
| BR (1) | BR112022024840A2 (enExample) |
| CA (1) | CA3181959A1 (enExample) |
| CL (1) | CL2022003534A1 (enExample) |
| MX (1) | MX2022015965A (enExample) |
| WO (1) | WO2021255622A1 (enExample) |
| ZA (1) | ZA202212128B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| WO2021194893A1 (en) | 2020-03-24 | 2021-09-30 | Cyrano Therapeutics, Inc. | Treatment of chemosensory dysfunction from a coronavirus infection |
| US20240173331A1 (en) | 2021-04-01 | 2024-05-30 | Alkem Laboratories Limited | Nasal compositions comprising alcaftadine |
| WO2023133460A1 (en) * | 2022-01-06 | 2023-07-13 | Cyrano Therapeutics, Inc. | Improved nasal administration of pharmaceutical formulations |
| WO2024228988A2 (en) * | 2023-05-02 | 2024-11-07 | Cyrano Therapeutics, Inc. | Treatment for taste and smell loss |
| GR1010821B (el) * | 2023-11-09 | 2024-11-15 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2053678T3 (es) | 1987-11-13 | 1994-08-01 | Asta Medica Ag | Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular. |
| IL101850A (en) | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them |
| DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| ES2258175T3 (es) * | 2001-12-05 | 2006-08-16 | Alcon, Inc. | Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis. |
| BRPI0615032A2 (pt) | 2005-09-01 | 2011-04-26 | Biolipox Ab | composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição |
| JP5292277B2 (ja) | 2006-03-31 | 2013-09-18 | ビスタコン・フアーマシユーチカルズ・エルエルシー | 眼アレルギーの処置 |
| US8569273B2 (en) * | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
| CN102283849A (zh) | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | 一种含有阿卡他定的药物组合物 |
| JP6294893B2 (ja) * | 2012-12-17 | 2018-03-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 炎症性及び／又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用 |
| MY191380A (en) * | 2013-09-13 | 2022-06-21 | Glenmark Specialty Sa | Stabilized fixed dose drug composition having mometasone and olopatadine |
| JP7191022B2 (ja) | 2017-07-28 | 2022-12-16 | 参天製薬株式会社 | アルカフタジン又はその塩を含有する水性医薬組成物 |
-
2021
- 2021-06-14 JP JP2022577618A patent/JP7791119B2/ja active Active
- 2021-06-14 AU AU2021291684A patent/AU2021291684A1/en active Pending
- 2021-06-14 MX MX2022015965A patent/MX2022015965A/es unknown
- 2021-06-14 US US17/997,656 patent/US20230218630A1/en active Pending
- 2021-06-14 KR KR1020227046470A patent/KR20230024928A/ko active Pending
- 2021-06-14 BR BR112022024840A patent/BR112022024840A2/pt unknown
- 2021-06-14 CN CN202180040805.7A patent/CN115701988A/zh active Pending
- 2021-06-14 CA CA3181959A patent/CA3181959A1/en active Pending
- 2021-06-14 EP EP21733564.5A patent/EP4164614A1/en active Pending
- 2021-06-14 WO PCT/IB2021/055222 patent/WO2021255622A1/en not_active Ceased
-
2022
- 2022-11-07 ZA ZA2022/12128A patent/ZA202212128B/en unknown
- 2022-12-12 CL CL2022003534A patent/CL2022003534A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3181959A1 (en) | 2021-12-23 |
| JP7791119B2 (ja) | 2025-12-23 |
| MX2022015965A (es) | 2023-03-14 |
| JP2023530166A (ja) | 2023-07-13 |
| US20230218630A1 (en) | 2023-07-13 |
| KR20230024928A (ko) | 2023-02-21 |
| AU2021291684A1 (en) | 2022-12-08 |
| EP4164614A1 (en) | 2023-04-19 |
| CN115701988A (zh) | 2023-02-14 |
| WO2021255622A1 (en) | 2021-12-23 |
| BR112022024840A2 (pt) | 2022-12-27 |
| CL2022003534A1 (es) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006190B (en) | Rimegepant for cgrp related disorders | |
| SA521430920B1 (ar) | P2x3 مشتقات أمينو كينازولين كمثبطات | |
| ZA202308388B (en) | Nasal compositions comprising alcaftadine | |
| CL2022003534A1 (es) | Combinación de alcaftadina y un corticoesteroide | |
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| MX2014013523A (es) | Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos. | |
| AU2017379247A8 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| BR112015018071A2 (pt) | estra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| EA202193343A1 (ru) | Вдыхаемая композиция, содержащая циклодекстрин, для применения при лечении назальных воспалений | |
| MX2021005967A (es) | Formas purificadas de rofecoxib, métodos de fabricación y uso. | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| BR112021020279A2 (pt) | Derivados de piridopirimidinas como inibidores de p2x3 | |
| NZ744942A (en) | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| PH12017501736B1 (en) | Indole derivatives | |
| PH12021551961A1 (en) | Nasal spray compositions and related treatment methods | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. |